TNF receptor superfamily member 12AGenealiases: CD266 · FN14 · TWEAKR
Q-omics provides the consensus-scored TNFRSF12A profile across patient tissues and cancer cell-line models. TNFRSF12A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TNFRSF12A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TNFRSF12A protein abundance shows 27,299 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, HNSC, and PDAC as cancer lineages where TNFRSF12A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF12A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF12A survival associations across molecular data types. TNFRSF12A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF12A RNA expression–survival associations across cancer types. High TNFRSF12A expression shows unfavorable associations in KIRC, HNSC, MESO, UVM, LUSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TNFRSF12A RNA expression.
This table summarizes TNFRSF12A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF12A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF12A shows lower tumor expression in KICH and higher tumor expression in HNSC, THCA, KIRP, COAD and STAD. The HNSC box plot shows higher TNFRSF12A RNA expression in tumor versus normal tissue (log2 FC = +2.457, t-test p < 0.001).
This table shows molecular features associated with TNFRSF12A in patient tissues and cancer cell lines. In patient samples, TNFRSF12A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF12A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
